CENTENNIAL, Colo. and ALISO VIEJO, Calif., March 15, 2011
/PRNewswire/ — LABS, Inc., the recognized leader in microbiology,
infectious disease screening, cell/molecular biology and
immunological testing for the transplant and biomedical sciences
communities, today announced an agreement with Ambry Genetics, a
global leader in molecular diagnostics and genomic services to the
healthcare and life sciences industries, that will allow the
organizations to provide superior testing services to a broader
base of clients in the reproductive health industry.
This partnership will make Ambry Genetics the preferred provider
of genetic carrier screening for LABS, Inc., giving LABS’ testing
clients access to AmbryScreen™, a genetic screening test used
to identify carriers of some of the most severe and common
childhood diseases affecting pan-ethnic populations.
“This partnership brings two premier laboratories together to
offer new donor and patient screening options combined with an
elite level of service that is unparalleled in the reproductive
health industry,” said Elizabeth Hearty, Chief Executive Officer of
LABS, Inc. “Ambry also brings to the table strong innovation and
cutting-edge technologies within the genetic diagnostic market and
that will effectively serve our clients.”
Ambry is a specialized laboratory focused solely on genetic
testing and diagnostic services. The Company operates in a highly
consultative manner with hands-on customer service and
individualized attention. LABS, Inc. has been serving the
transplant community for nearly 30 years in the areas of infectious
disease, immunogenetics and microbiology. LABS, Inc. brings
unparalleled consultative and regulatory expertise to its
customers.
“We are excited about partnering with LABS, Inc. to give more
people access to this critical genetic test,” said Steven Keiles,
Vice President of Diagnostic Services of Ambry Genetics. “LABS,
Inc.’s reputation for excellence in the
‘/>”/>